UB-621

BIOLOGICAL3 trials

Sponsors

United BioPharma, UBP Greater China (Shanghai) Co., Ltd

Conditions

Genital HerpesHerpes Simplex Virus InfectionRecurrent Genital Herpes

Phase 1

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of UB-621 in Healthy Volunteers

CompletedNCT02346760

United BioPharmaHerpes Simplex Virus Infection

Start: 2015-12-31End: 2017-01-31Updated: 2019-04-18

Phase 2

A Phase 2 Trial to Evaluate the Safety and Efficacy of UB-621

United BioPharmaGenital Herpes

Start: 2023-06-01End: 2024-06-30Target: 80Updated: 2022-10-03

UB-621, a New Type of Anti-herpes Simplex Virus (HSV) Monoclonal Antibody for the Use in the Treatment of Adult Recurrent HSV-2 Infections of the Genitals

UBP Greater China (Shanghai) Co., LtdRecurrent Genital Herpes

Start: 2023-10-01End: 2025-01-31Target: 44Updated: 2022-05-18